Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Miami Doctor Pioneers Innovative Stem Cell Therapies For Parkinson's Disease, Spinal Stenosis And Degenerative Eye Disorders


News provided by

Center for Regenerative Medicine

May 17, 2017, 08:00 ET

Share this article

Share toX

Share this article

Share toX

MIAMI, May 17, 2017 /PRNewswire/ -- A Miami doctor who has developed an international reputation for medical innovation over the last 18 years has become a pioneer in the burgeoning and critically important field of stem cell therapy.

In Autologous Stem Cell Therapy the patient is recipient as well as donner
In Autologous Stem Cell Therapy the patient is recipient as well as donner

Alimorad Farshchian, M.D., founder and medical director of The Center for Regenerative Medicine, founded in 1999, has developed innovative, safe and effective stem cell treatments for Parkinson's Disease, spinal stenosis and other physical ailments, such as back and knee problems. More recently, he has developed stem cell-derived eye drops that have successfully treated a range of eye disorders, including retinitis pigmentosa.

Since 2006, Dr. Farshchian has treated more than 11,000 patients in more than 50 countries with his proprietary stem cell therapies. Despite his major innovation and success with stem cell therapies, he is best-known worldwide for successfully treating the late Michael Jackson for his addiction to prescription painkillers and also for an ankle injury before what would have been the new tour Jackson planned before his death.

Stem cells are the body's most fundamental raw materials -- the cells from which all other cells with specialized functions are generated. They either become new stem cells or specialized cells, such as retina cells for the eyes. No other cell in the human body has the ability to generate new types of cells that address specific bodily functions.

Beginning in 1999, Dr. Farshchian, a member of the American Academy of Anti-Aging Medicine, began a quest to develop new and more effective treatments for neurodegenerative diseases such as Parkinson's Disease. In 2006, he began experimenting with revolutionary stem cell treatments that involve using the patient's own stem cells, known as autologous stem cells, which are reinjected into the patient's body after minimal processing.

"I've experienced great improvement as a result of the stem cell treatments," says 62-year-old Sharon Davis of Cocoa, Florida, who was diagnosed with Parkinson's Disease three and a half years ago. After taking medications for more than three years that did not eliminate her symptoms and also had unpleasant side effects, she sought out Dr. Farshchian after he successfully treated her 37-year-old daughter, Heather Fleckinger, who had suffered from chronic and severe lower back problems for five years.

A series of three monthly stem cell injections significantly relieved Ms. Davis's symptoms, especially the shaking she was experiencing on her right side, and reduced her need for prescription medications. "Based on how much he helped me, I tell everybody I know to go see him," says Ms. Davis, who is continuing treatment in the hope her symptoms will be completely alleviated, ending her need for any medications.

Her daughter, Ms. Fleckinger, says, "I feel like Dr. Farshchian saved my life. Before I went to see him, I wore a back brace and took daily medications, but my back problems still prevented me from doing my job as a horse trainer and I had to wear a back brace almost constantly. Over a five-year period, I also tried chiropractors and acupuncture, but nothing worked."

Then, she says, a series of three stem cell injections from Dr. Farshchian over a one-week period cured her. "Within three weeks, my back felt much better," she says. "And after four weeks, it didn't hurt at all. I could hardly believe it. I consider it a miracle." She returns for follow-up "booster shots" every six to 12 months.

Rose Rubino, a 69-year-old business owner from Cape Canaveral, has been treated with Dr. Farshchian's stem cell therapies over the last seven years for knee problems, severe arthritis, and spinal stenosis.

"The first time I went to see him, I was scheduled for knee replacement surgery," Ms. Rubino says. "But I ended up being able to avoid surgery because of the incredible result I got from the stem cell injections." She received three injections over a one-week period.

Three months later, her 54-year-old sister suffered a frozen shoulder. Doctors told her the condition required arthroscopic surgery. Instead, based on Ms. Rubino's recommendation, she saw Dr. Farshchian, who treated her successfully with a single stem cell injection. "So she was able to avoid surgery, just like I was," Ms. Rubino says.

Over the past five years, Dr. Farshchian has also successfully treated Ms. Rubino for arthritis and spinal stenosis.  "Dr. Farshchian saved my life, as far as I'm concerned," she says. "Nobody ever told me that as I aged, I would develop all these painful physical ailments that would supposedly require surgery. And every time, Dr. Farshchian's stem cell treatments worked. I consider myself his unofficial spokesperson, because as far as I'm concerned he performed multiple miracles in my life. So I tell the world about him, every chance I get."

Dr. Farshchian's latest progress is in the field of optical regeneration. He has developed proprietary eye drops, trademarked as iFarshchian Drops™, to treat retinitis pigmentosa, a genetic disorder that involves a breakdown and loss of cells in the retina.

The drops are uniquely developed for each patient from his or her own stem cells and are engineered to penetrate the sclera, or white outer layer of the eyeball, in order to find damaged eye cells and rejuvenate them.

Dr. Farshchian stresses that recently reported and serious complications from therapy at a South Florida clinic that injected stem cells into the eyes of patients were the result of flawed delivery of the therapy, rather than the therapy itself, which has been proven safe and successful in ongoing clinical trials at University of California at Irvine and at RIKEN Laboratory in Kobe, Japan. He also emphasizes that his eye drops are less invasive and safer than injections.

This spring, Dr. Farshchian's eye drops successfully treated 89-year-old James Enochs of Prince George, VA for degenerative eye disease.  "I've already had significant improvement in my ability to read an eye chart," says Enochs, who was successfully treated with stem cell therapy by Dr. Farshchian for chronic knee problems seven years ago. "My eyes had been very sensitive to wind and light. And I've noticed a significant improvement in that sensitivity. I can only speak about the eye drops from my own experience. But for me, they have already delivered pretty remarkable results." He will now continue to use the drops at home.

"Dr. Farshchian is a very brilliant and innovative doctor," Enochs says. "I was just about as skeptical as you could be the first time I came to Miami seven years ago for treatment on my knees. But I had a huge success with my knees, and was able to avoid the surgery that my orthopedist wanted to perform. Now I've also had success with my eyes. So I'm very impressed with his work with stem cells. I'm not a skeptic anymore."

Because Dr. Farshchian uses only autologous stem cells -- those taken from a patient's own body -- the therapies are neither restricted nor regulated by the Food & Drug Administration. But, Dr. Farshchian points out, he fully complies with all stem cell-related FDA recommendations.

"The three primary disorders that I treat with stem cells -- retinitis pigmentosa, Parkinson's Disease, and spinal stenosis, are difficult to treat traditionally because they are stubbornly resistant to surgery," Dr. Farshchian says. "That means that most patients with those conditions are in dire need of a new alternative that works. And very few of them are aware yet of the dramatic breakthroughs being made with stem cell therapies."

His stem cell treatments are not Dr. Farshchian's first major medical innovation. Almost 20 years ago, he coined the term "orthopedic regenerative medicine" to describe the highly effective new treatments he developed for common ailments such as arthritis.

The Center for Regenerative Medicine is located at 1001 NE 125th Street in North Miami. For more information, call (305) 891-4686 or visit ArthritisUSA.net.

SOURCE Center for Regenerative Medicine

Related Links

http://arthritisusa.net

21%

more press release views with 
Request a Demo

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.